Stockscreener 앱 받기
1.25
58.23%
0.46
전일 마감가:
$0.79
열려 있는:
$0.8079
하루 거래량:
3.77M
Relative Volume:
3.09
시가총액:
$4.25M
수익:
$202.00K
순이익/손실:
$-28.96M
주가수익비율:
-2.0833
EPS:
-0.6
순현금흐름:
$-21.85M
1주 성능:
+9.65%
1개월 성능:
-1.57%
6개월 성능:
-53.14%
1년 성능:
+802.78%
1일 변동 폭
$0.7801
$1.38
1주일 범위
$0.7653
$1.38
52주 변동 폭
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
1.25 | 2.69M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - Bitget
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
Pancreatic cancer focus: AIM ImmunoTech CEO joins Webull live webinar - Stock Titan
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Announces Positive Phase 2 Trial Results fo - GuruFocus
AIM ImmunoTech’s $12M Rights Offering: Implications and Prospects - StocksToTrade
Why Is AIM ImmunoTech Stock Up Today? - TipRanks
AIM ImmunoTech Rights Offering Targets $12 Million Boost - timothysykes.com
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | AIM Stock News - Longbridge
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update - TipRanks
AIM ImmunoTech Inc Provides Interim Update on DURIPANC Study - TradingView
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire
Experimental drug combo shows survival promise in pancreatic cancer trial - Stock Titan
Pricey healthcare stocks with halting momentumlow momentum and high valuation (AIM:NYSE) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering - The Manila Times
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewswire
AIM ImmunoTech Stock Trading Halted, Pending Material News Release - marketscreener.com
AIM ImmunoTech Adjusts Class E Warrant Terms After Dividend - TipRanks
AIM ImmunoTech Inc Modifies Class E and F Warrants - TradingView
Why AIM ImmunoTech Inc. (HXB) stock gets analyst attentionSupport Zone Identification & The Smart Money Is Buying These Picks - bollywoodhelpline.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
AIM ImmunoTech Highlights Ampligen Development Risks and Plans - The Globe and Mail
Trend Recap: How AIM ImmunoTech Inc stock compares with tech leadersDollar Strength & Entry Point Confirmation Signals - Bộ Nội Vụ
AIM ImmunoTech (NYSEAMERICAN:AIM) Upgraded at Zacks Research - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Rate Cut: Is AIM ImmunoTech Inc HXB stock undervalued after correctionMarket Activity Summary & Free Expert Verified Stock Movement Alerts - Bộ Nội Vụ
AIM ImmunoTech Inc.: - MarketScreener
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AIM ImmunoTech (NYSEAMERICAN:AIM) Shares to Split on Friday, January 9th - Defense World
AIM ImmunoTech: One Shr for Every 1,000 Shrs or for Every Outstanding Option or Warrant Having a Right to Stk Dividends >AIM - 富途牛牛
AIM ImmunoTech Announces Stock Dividend - The Manila Times
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):